Want to see KR:003220 full AI Analyst Report?

Daewon Pharmaceutical Co., Ltd (003220) Price & Analysis

― Followers

003220 Stock Chart & Stats

$8680.00

$980.00(12.73%)

Oct 30, 2026

―

Day’s Range― - ―

52-Week Range$7,060.00 - $13,670.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)98.86K

Market Cap

₩189.25B

Enterprise Value$307.33B

Total Cash (Recent Filing)₩66.18B

Total Debt (Recent Filing)₩189.15B

Price to Earnings (P/E)70.8

Beta-0.03

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.88%

Share Statistics

EPS (TTM)122.58

Shares Outstanding22,427,584

10 Day Avg. Volume222,290

30 Day Avg. Volume98,861

Financial Highlights & Ratios

PEG Ratio1.69

Price to Book (P/B)0.96

Price to Sales (P/S)0.42

P/FCF Ratio18.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)450

Revenue Forecast (FY)₩630.50B

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthThe company is experiencing substantial top-line acceleration, indicating stronger sales across its pharmaceutical portfolio and distribution channels. If maintained, this growth can expand operating scale, support broader market reach, and provide a larger revenue base for restoring profitability over the next several quarters.

Solid Gross MarginA gross margin near 45% shows that the underlying product portfolio retains meaningful economics before operating expenses. This provides a foundation for earnings recovery if the company can control its operating cost base and convert strong revenue growth into sustainable operating profit.

Manageable LeverageDebt remains manageable relative to equity, limiting immediate balance-sheet pressure and preserving some flexibility for ongoing pharmaceutical operations and development. Stable equity and sector-appropriate leverage give the company capacity to address profitability issues without an evidently excessive debt burden.

Bears Say

Negative Operating ProfitabilityNegative EBIT indicates that current operating costs exceed the profit generated by the business despite rapid revenue growth. This weakens earnings quality and shows that sales expansion is not yet translating into durable operating leverage, making margin recovery a central execution requirement.

Weak Free Cash FlowSmall and declining free cash flow limits internally generated funds available for research, investment, debt service, and shareholder returns. The history of inconsistency, including negative free cash flow in 2024, indicates that reported business activity is not reliably converting into surplus cash.

Compressed ReturnsVery low return on equity suggests that the company is currently using its capital inefficiently, reducing the economic benefit of continued revenue expansion. With leverage higher than in prior years, weak returns also leave less room for balance-sheet improvement unless profitability strengthens.

Daewon Pharmaceutical Co., Ltd News

Daewon Pharmaceutical Plans Two‑Day Institutional IR Roadshow in Yeouido

An announcement from Daewon Pharmaceutical Co., Ltd ( ($KR:003220) ) is now available. Daewon Pharmaceutical will hold a...

2M ago

003220 FAQ

What was Daewon Pharmaceutical Co., Ltd’s price range in the past 12 months?

Daewon Pharmaceutical Co., Ltd lowest stock price was $7060.00 and its highest was $13670.00 in the past 12 months.

What is Daewon Pharmaceutical Co., Ltd’s market cap?

Daewon Pharmaceutical Co., Ltd’s market cap is ₩189.25B.

When is Daewon Pharmaceutical Co., Ltd’s upcoming earnings report date?

Daewon Pharmaceutical Co., Ltd’s upcoming earnings report date is Nov 12, 2026 which is in 11 days.

How were Daewon Pharmaceutical Co., Ltd’s earnings last quarter?

Daewon Pharmaceutical Co., Ltd released its earnings results on Aug 07, 2026. The company reported $187.921 earnings per share for the quarter.

Is Daewon Pharmaceutical Co., Ltd overvalued?

According to Wall Street analysts Daewon Pharmaceutical Co., Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Daewon Pharmaceutical Co., Ltd pay dividends?

Daewon Pharmaceutical Co., Ltd pays a Annually dividend of $250 which represents an annual dividend yield of 2.88%. See more information on Daewon Pharmaceutical Co., Ltd dividends here

What is Daewon Pharmaceutical Co., Ltd’s EPS estimate?

Daewon Pharmaceutical Co., Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Daewon Pharmaceutical Co., Ltd have?

Daewon Pharmaceutical Co., Ltd has 22,427,584 shares outstanding.

What happened to Daewon Pharmaceutical Co., Ltd’s price movement after its last earnings report?

Daewon Pharmaceutical Co., Ltd reported an EPS of $187.921 in its last earnings report. Following the earnings report the stock price went up 4.75%.

Which hedge fund is a major shareholder of Daewon Pharmaceutical Co., Ltd?

Currently, no hedge funds are holding shares in KR:003220

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Daewon Pharmaceutical Co., Ltd

Established in 1958 and headquartered in Seoul, South Korea, Daewon Pharmaceutical Co., Ltd. is a well-regarded pharmaceutical enterprise specializing in the development, manufacturing, and distribution of a comprehensive range of medications and medical supplies within the South Korean market. Its extensive product portfolio targets diverse therapeutic fields, encompassing cardiovascular, respiratory, anti-infective, oncology, and neuropsychiatric conditions. Key offerings include Oramin-F Soft Cap, a notable multivitamin; Pelubi Tablet, an NSAID specifically formulated for pain management; Freefol-MCT Inj., a microemulsion propofol designed to prevent exogenous bacterial infections; Megex-I Susp, a medication that supports the nutritional needs of cancer patients experiencing subalimentation; Trigel Susp, an effective treatment for gastritis and duodenal ulcers; and Renamezin Cap, a spherical carbonaceous adsorbent for managing chronic kidney disease. Furthermore, Daewon Pharmaceutical extends its global footprint by exporting its products to approximately 45 countries, predominantly across Asia, Central and South America, and the Middle East.